Since NSPX shut down operations in Feb 18 they have filed 27 SEC reports detailing the happenings of the company and are now current. I agree they have filed no "BOGUS" press releases to pump the company. It may appear that they are doing what many pre-revenue clinical bio companies do that is survive until something happens with their IP.